Demant CEO won't rule out dismissals following divestment of implant division
The 700 people employed at Demant’s surgical division, Oticon Medical, have an uncertain future ahead after the parent company announced its intention to sell the unit to Cochlear. CEO Søren Nielsen says some people might be transferred and others reshuffled within Demant, but he won’t reject having to resort to dismissals.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
If any worried faces were detected this morning among the around 700 people working at the implant division of hearing aid manufacturer Demant, it is well understood why.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cochlear relieves Demant of loss-making implant division
For subscribers
Demant to divest hearing implant division to Cochlear
For subscribers
.jpg&w=384&q=75)
